LT3562935T - Trimatis in vitro alveolinis plaučių modelis, ir jo naudojimas nustatant ir (arba) prognozuojant įkvėpiamųjų produktų sensibilizuojančius poveikius - Google Patents

Trimatis in vitro alveolinis plaučių modelis, ir jo naudojimas nustatant ir (arba) prognozuojant įkvėpiamųjų produktų sensibilizuojančius poveikius

Info

Publication number
LT3562935T
LT3562935T LTEPPCT/EP2017/084583T LT17084583T LT3562935T LT 3562935 T LT3562935 T LT 3562935T LT 17084583 T LT17084583 T LT 17084583T LT 3562935 T LT3562935 T LT 3562935T
Authority
LT
Lithuania
Prior art keywords
inhalated
forecasting
identifying
dimensional
products
Prior art date
Application number
LTEPPCT/EP2017/084583T
Other languages
English (en)
Inventor
Aline CHARY
Arno GUTLEB
Tommaso SERCHI
Brunehilde BLÖMEKE
Original Assignee
Luxembourg Institute Of Science And Technology (List)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luxembourg Institute Of Science And Technology (List) filed Critical Luxembourg Institute Of Science And Technology (List)
Publication of LT3562935T publication Critical patent/LT3562935T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0688Cells from the lungs or the respiratory tract
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0697Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114T cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121Dendritic cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157Monocytes, macrophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/27Lung cells, respiratory tract cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/28Vascular endothelial cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • C12N2503/04Screening or testing on artificial tissues

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/EP2017/084583T 2016-12-27 2017-12-26 Trimatis in vitro alveolinis plaučių modelis, ir jo naudojimas nustatant ir (arba) prognozuojant įkvėpiamųjų produktų sensibilizuojančius poveikius LT3562935T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU93401A LU93401B1 (en) 2016-12-27 2016-12-27 Three-dimensional in vitro lung model, process for preparing said model, and its use for determining and/or predicting the sensitizing effects of inhalable products
PCT/EP2017/084583 WO2018122219A1 (en) 2016-12-27 2017-12-26 Three-dimensional in vitro alveolar lung model, process for preparing said model, and its use for determining and/or predicting the sensitizing effects of inhalable products

Publications (1)

Publication Number Publication Date
LT3562935T true LT3562935T (lt) 2022-01-25

Family

ID=57629611

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2017/084583T LT3562935T (lt) 2016-12-27 2017-12-26 Trimatis in vitro alveolinis plaučių modelis, ir jo naudojimas nustatant ir (arba) prognozuojant įkvėpiamųjų produktų sensibilizuojančius poveikius

Country Status (19)

Country Link
US (1) US11566233B2 (lt)
EP (1) EP3562935B8 (lt)
JP (1) JP6934533B2 (lt)
KR (1) KR102185041B1 (lt)
CN (1) CN110168075B (lt)
AU (1) AU2017385595B2 (lt)
BR (1) BR112019013143A2 (lt)
CA (1) CA3046351A1 (lt)
DK (1) DK3562935T3 (lt)
ES (1) ES2901618T3 (lt)
HR (1) HRP20212005T1 (lt)
HU (1) HUE056706T2 (lt)
IL (1) IL267633B2 (lt)
LT (1) LT3562935T (lt)
LU (1) LU93401B1 (lt)
PL (1) PL3562935T3 (lt)
PT (1) PT3562935T (lt)
SI (1) SI3562935T1 (lt)
WO (1) WO2018122219A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020141204A2 (en) * 2019-01-03 2020-07-09 Senzagen Ab Analytical methods and arrays for use in the same
JPWO2021193700A1 (lt) * 2020-03-25 2021-09-30
GB202005154D0 (en) 2020-04-07 2020-05-20 Univ Of Hertfordshire Higher Education Corporation Method and model
JP7799306B2 (ja) * 2020-10-27 2026-01-15 学校法人東京医科大学 被検物質の感作性検出方法、感作抑制物質のスクリーニング方法、および生体投与用組成物の製造方法
LU501055B1 (en) 2021-12-21 2023-06-21 Luxembourg Inst Science & Tech List Aerosol deposition device
LU501054B1 (en) 2021-12-21 2023-06-21 Luxembourg Inst Science & Tech List Aerosol deposition device
DE102022120500B3 (de) 2022-08-15 2023-10-12 FILK Freiberg Institute gGmbH Verfahren und Vorrichtung zur Herstellung von Hohlkugeln aus Kollagen und Kollagenderivaten und Hohlkugeln aus Kollagen und Gelatine
LU503396B1 (en) 2023-01-27 2024-07-29 Luxembourg Inst Science & Tech List Aerosol deposition device
EP4638693A1 (en) 2022-12-23 2025-10-29 Luxembourg Institute Of Science And Technology (List) Aerosol deposition device
CN117363560A (zh) * 2023-10-10 2024-01-09 安徽理工大学第一附属医院 一种煤尘纳米颗粒暴露致肺损伤体外细胞模型及其构建方法和应用
LU507930B1 (en) 2024-08-05 2026-02-05 Luxembourg Institute Of Science And Tech Serum-free culture medium for the culture of human monocytic cells and method using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009048661A1 (en) * 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
CN103060266A (zh) * 2012-12-14 2013-04-24 广州呼吸疾病研究所 人肺泡ii型上皮细胞的分离培养方法
WO2015005349A1 (ja) * 2013-07-09 2015-01-15 国立大学法人東京大学 細胞培養支持体、細胞培養装置、細胞培養キット、及び細胞シート

Also Published As

Publication number Publication date
WO2018122219A1 (en) 2018-07-05
AU2017385595A1 (en) 2019-07-04
AU2017385595B2 (en) 2024-03-14
PT3562935T (pt) 2021-12-09
CN110168075A (zh) 2019-08-23
LU93401B1 (en) 2018-07-24
RU2019119427A (ru) 2021-01-29
KR20190096415A (ko) 2019-08-19
EP3562935A1 (en) 2019-11-06
EP3562935B8 (en) 2021-12-29
HUE056706T2 (hu) 2022-03-28
HRP20212005T1 (hr) 2022-04-01
CN110168075B (zh) 2024-01-05
US11566233B2 (en) 2023-01-31
IL267633B2 (en) 2023-11-01
US20190376048A1 (en) 2019-12-12
SI3562935T1 (sl) 2022-04-29
IL267633B1 (en) 2023-07-01
RU2019119427A3 (lt) 2021-02-04
BR112019013143A2 (pt) 2019-12-10
ES2901618T3 (es) 2022-03-23
KR102185041B1 (ko) 2020-12-02
PL3562935T3 (pl) 2022-02-07
JP2020503892A (ja) 2020-02-06
JP6934533B2 (ja) 2021-09-15
CA3046351A1 (en) 2018-07-05
IL267633A (en) 2019-08-29
EP3562935B1 (en) 2021-10-06
DK3562935T3 (da) 2021-12-20

Similar Documents

Publication Publication Date Title
LT3562935T (lt) Trimatis in vitro alveolinis plaučių modelis, ir jo naudojimas nustatant ir (arba) prognozuojant įkvėpiamųjų produktų sensibilizuojančius poveikius
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
IL251821A0 (en) Cannabis extracts and methods of preparing and using same
HUE040696T2 (hu) Hidroxialkil-szubsztituált feniltriazol-származékok és alkalmazásuk
SI3258951T1 (sl) Anti-pvrig protitelesa in metode uporabe
HUE053908T2 (hu) Amid-szubsztituált piridiniltriazol-származékok és alkalmazásuk
HUE052771T2 (hu) C10orf54 elleni antitestek és alkalmazásuk
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
SI3116909T1 (sl) Molekule protiteles na LAG-3 in njih uporaba
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
SI3394065T1 (sl) Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega
LT3532499T (lt) Antikūnai prieš il-33 ir jų panaudojimas
KR20180084867A (ko) 음향 프리프레그, 코어 및 복합 물품 및 이의 사용 방법
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
DK3152296T3 (da) Human hepatisk 3d-samkulturmodel og anvendelser deraf
HRP20211272T8 (hr) 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda
HUE039858T2 (hu) 2,6-Szubsztituált purinszármazékok és alkalmazásuk proliferatív rendellenességek kezelésében
SI3290441T1 (sl) RGMA-vezavni protein in njegova uporaba
LT3064498T (lt) Pirazolpirimidono arba piroltriazono dariniai, jų paruošimo būdas ir jų farmacinis panaudojimas
SI3102185T1 (sl) Nanosuspenzija naravnih materialov in postopek priprave le-te
HUE063621T2 (hu) ß-interferon elleni ellenanyagok és alkalmazásuk
HUE052074T2 (hu) Mutáns VIII-as faktor készítmények és módszerek
DK3166945T3 (da) Hidtil ukendte triazolopyrimidinon- eller triazolopyridinderivater og anvendelse deraf
LT3512849T (lt) 7-pakeistieji 1-aril-naftiridin-3-karboksamidai ir jų naudojimas
HUE045192T2 (hu) 6-morfolinil-2-pirazolil-9H-purin származékok és felhasználásuk PI3K inhibitorokként